Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653962 | 0.89 | MEN1 (0.47) | KMT2AMEN1LMNAGAASMN1; SMN2 | |
| SCHEMBL10153609 | 0.89 | MEN1 (0.47) | KMT2AMEN1LMNAGAASMN1; SMN2 | |
| SCHEMBL9959487 | 0.86 | HTT (0.43) | KMT2AMEN1GAAMAPTALDH1A1 | |
| SCHEMBL11788802 | 0.86 | KMT2A (0.57) | KMT2ATSHRMEN1LMNAGAA | |
| SCHEMBL9953409 | 0.81 | POLB (0.50) | TSHRSMN1; SMN2ALDH1A1POLBKCNA5 | |
| SCHEMBL10153729 | 0.80 | MAPT (0.46) | KMT2ATSHRMAPTALDH1A1POLB | |
| SCHEMBL9958705 | 0.79 | HDAC4 (0.62) | KMT2ATSHRMEN1LMNAGAA | |
| SCHEMBL19380274 | 0.78 | HDAC4 (0.44) | KMT2ATSHRMEN1LMNAGAA | |
| SCHEMBL31653994 | 0.77 | KCNA5 (0.48) | KMT2AMEN1LMNAGAASMN1; SMN2 | |
| SCHEMBL10153606 | 0.77 | KCNA5 (0.48) | KMT2AMEN1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017161133-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2012085003-A1 | 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085003-A1 | 2-HYDROXYISOQUINOLINE-1,3(2H,4H)-DIONES AND RELATED COMPOUNDS USEFUL AS HIV REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | HCCS, HAVCR2, HDGF | KMT2A 2169/4885TSHR 4437/4885MEN1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.